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Detection of a clonal T cell receptor (TCR) gene rearrangement is used in the diagnosis of primary cutaneous T cell
lymphomas (CTCL) whereas chromosomal aberrations serve as a diagnostic tool for leukaemias and nodal
lymphomas. To what extent both approaches specify the same cell population remains unknown. We investigated
the coincidence of TCR clonality with complex clonal chromosomal aberrations, indicating qualitative alteration of
the affected cells, in 17 CTCL patients. Out of 41 skin, blood, and lymph node samples studied, 34 gave results in
chromosome and TCR analyses. With 88%, most specimens revealed corresponding results by both techniques (27
of 34 clonal, three of 34 non-clonal). In two patients, analysis of micro-dissected cells demonstrated that neoplastic
T cells bear both a dominant TCR rearrangement and a complex chromosomal aberration. The cutaneous clone was
found in blood samples of 11 of 12 patients (including early stages), and investigation of follow-up skin and blood
samples indicated persistence of the T cell clone in 11 of 14 cases. In conclusion, we show that dominant TCR
clones and chromosomal clones converge in all stages of CTCL. These clones disseminate into blood and skin at
early disease stages and persist despite therapy. The coexistence of a dominant TCR clone and a clonal
chromosomal aberration can thus be used as a hallmark of malignancy.
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Primary cutaneous T cell lymphomas (CTCL) represent a
heterogeneous group of non-Hodgkin lymphomas whose
pathogenesis is poorly understood. During the past
decades, up to 3-fold increases in CTCL incidence have
been observed in the western world (Weinstock and Horm,
1988; Siegel et al, 2000; Vakeva et al, 2000). The most
common CTCL is mycosis fungoides (MF), which is difficult
to diagnose in its early presentation since it may clinically
and histologically resemble eczema or parapsoriasis (Siegel
et al, 2000).
In the latter connection, detection of a clonal T cell
receptor (TCR) gene rearrangement has become widely
used. By means of PCR and high-resolution electrophor-
esis, a TCR clone can be demonstrated in skin biopsies of
up to 90% of MF cases (Trainor et al, 1991; Bottaro et al,
1994), and its detection at the initial diagnosis has been
found to be an independent negative predictive marker of
treatment response (Delfau-Larue et al, 1998). Moreover,
the cutaneous TCR clone is detectable in the peripheral
blood already in about 40% of patients with early MF
(stages IA–IIA) (Theodorou et al, 1995; Muche et al, 1997;
Fraser-Andrews et al, 2000).
However, detection of a TCR clone does not unan-
imously mean malignancy, and the presence of additional
different clonal TCR gene rearrangements in skin and lymph
node samples of about one-third of MF patients may be
confusing (Vega et al, 2002). Clonal T cell expansions have
been identified in a substantial portion of blood samples
derived from healthy individuals and patients with benign
diseases, as well as in skin specimens from benign
dermatoses (Posnett et al, 1994; Kolowos et al, 1997;
Muche et al, 1999; Lukowsky et al, 2000). Here, the accu-
mulation of T cell clones was found to be age-dependent
and started earlier as well as was more pronounced in the
CD8-positive fraction (Wack et al, 1998).
Besides TCR rearrangements, the detection of clonal
chromosomal aberrations designates a clonal T cell expan-
sion. In CTCL, a variety of aberrations have been found in
the vast majority of patients and even in some patients with
large-plaque parapsoriasis (LPP) (Whang-Peng et al, 1979;1Both authors contributed equally to this study.
Abbreviations: CGH, comparative genome hybridization; CTCL,
cutaneous T cell lymphoma; FFA, fluorescence fragment analysis;
FISH, fluorescent in situ hybridization; LPP, large-plaque para-
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Karenko et al, 1997). Moreover, their detection may precede
relapse or progression of the disease (Whang-Peng et al,
1979; Karenko et al, 1997). Chromosomal clones, especially
with complex somatic alterations, indicate qualitative and
functional alteration of the affected cells, and occur very
rarely in blood and normal tissue of healthy adults (Johnson
et al, 1998; Broberg et al, 2001; Rubes et al, 2002; Karenko
et al, 2003).
The correlation of TCR clonality and chromosomal
clonality has been previously described by Bagot et al
(1998), showing trisomy 7 in a CTCL-derived tumor cell line
by fluorescent in situ hybridizations (FISH) in combination
with the detection of three clonally rearranged TCRb
segments in the cell line and in corresponding skin and
blood samples, but not in a corresponding cytotoxic cell
line. However, the significance of solitary trisomy 7 as a
marker of malignancy is controversial, as it has also been
observed in some non-malignant tissues and may correlate
with age (Broberg et al, 2001). Since the coexistence of
clonal chromosomal abnormalities and TCR clones had not
been investigated in a large series of samples in vivo, we
explored them in 41 samples derived from skin, blood, or
lymph nodes of 17 patients suffering from CTCL.
Results and Discussion
Out of the 41 CTCL samples, 34 could be analyzed for
chromosome aberrations and 40 were positive by PCR for
TCRg rearrangements. The majority of the 34 specimens,
which were successfully studied by both approaches,
revealed corresponding results for TCR and chromosomal
clonality (88%, 27 of 34 clonal, three of 34 non-clonal, Table
I). Whether the same cell bearing the clonal TCR rearrange-
ment also had clonal chromosomal aberrations was further
demonstrated in two patients (#15 and #16). Both showed
clonal trisomy 8 as part of a very complex karyotype, which
thus could be used as a selection marker for the chromo-
somally clonal cells. Here, identical clonal fragment lengths
and TCRg sequences were detected in DNA extracted from
the whole tissue sample and from single, trisomy 8-positive
cells micro-dissected from touch preparations of the lymph
node (#15) or skin (#16) samples (Fig 1). Out of the nine
control samples taken from healthy volunteers and psoriasis
patients, none was found to bear a TCR or chromosomal
clone (Table I). Thus, at least in CTCL, the occurrence of
TCR clonality is strongly associated with the occurrence of
complex clonal aberrations of chromosomes or, vice versa,
complex chromosomal aberrations arise predominantly in
clonally expanded T lymphocytes.
All of the divergent specimens were clonal by TCR
analysis only (patients #01, 04, 05, 14) and were derived
from peripheral blood. Since the TCR clones found in two of
them (#04 and #14) differed from the primary TCR clone,
this discrepancy may be due to the occurrence of reactive
clonal T cells as previously described in the peripheral blood
of CTCL patients (Delfau-Larue et al, 2000; Beylot-Barry
et al, 2001) or to the evolution of subclones from a dominant
clone as suggested by Vega et al (2002). However, as
indicated by the detection of chromosomal clonality in a
follow-up sample of #01, sensitivity limits of G-banding and
MFISH or tumour cell death prior to chromosomal analysis
in vitro may also be an explanation for this observation.
Interestingly, in patient #06, showing a chromosomal clone
and TCR clone in the skin, chromosomal analysis of two
available blood samples identified a single cell in the earlier
blood sample to bear the same aberrations as observed in
the skin, whereas TCR analysis revealed no clonality.
Corresponding skin and blood specimens were available
in 12 of 17 CTCL patients. Here, FFA revealed identical TCR
clones in the skin and blood (and lymph node of #15) of nine
patients, whereas in three patients a different (#04, #10) or
no blood clone (#06) was detected. When successful,
chromosomal analysis confirmed the TCR data in the nine
above-mentioned patients and identified one additional
patient (#04) to bear identical clones in the skin and blood.
Since identical clones were found in CTCL stages IA–IVB,
previous TCR data demonstrating an early dissemination of
the T-cell clone in both skin and blood (Muche et al, 1997;
Karenko et al, 1997, 1999, 2001; Fraser-Andrews et al,
2000; Beylot-Barry et al, 2001) are now for the first time
confirmed by parallel chromosomal analyses.
Analysis of follow-up samples revealed persistence of
the initial TCR/chromosomal clone in 11 of 14 patients
despite therapy and even if temporary complete clinical
remission was achieved (Table I). This long-standing
persistence of initial T cell clones stands in line with pre-
viously published data (Vega et al, 2002; Poszepczynska-
Guigne et al, 2003), and indicates that clonal cells were not
targeted by current therapies nor were they sensitive to
therapy-induced apoptosis as currently suggested (Kacinski
and Flick 2001; Nikolova et al, 2002).
In conclusion, our data show that dominant TCR clones
and chromosomal clones converge in all stages of CTCL.
These clones disseminate into blood and skin at early
disease stages and persist despite current therapeutic
modalities. As proven in two cases at the single cell level,
neoplastic T lymphocytes bear both a dominant TCR re-
arrangement and microscopically detectable chromosomal
aberrations as a hallmark of malignancy.
Material and Methods
Patients and samples Forty-one blood, skin, and lymph node
biopsy samples were obtained, after written informed consent and
in the context of routine examinations, from 17 CTCL patients
(three female, mean age 52 y, range 19–79 y, and 14 male, mean
age 55 y, range 20–87 y): 16 with MF or Sezary´’s syndrome (SS),
and one with subcutaneous panniculitis-like CTCL (s.c. CTCL).
Patients were diagnosed and treated according to the EORTC
classification (Willemze et al, 1997) at the Department of
Dermatology, Helsinki University Hospital, and samples were taken
prior to and between any therapy (psoralen UV-A treatment (PUVA),
interferon-a, electron beam, or combinatorial chemotherapy)
during a follow-up, of 2 mo to 4 y (Table I). Nine additional blood
samples from voluntary donors (healthy individuals, n¼ 5; patients
with psoriasis vulgaris, n¼ 4) served as controls. The study was
approved by the Ethical Review Board of Helsinki University
Hospital. Detailed information about the karyotypes or therapy
given and response to therapy during follow-up have been
previously published for the following patients: #01(Karenko et al,
1997, 1999), #03, #04, #08 (Karenko et al, 1997, 2001, 2003;
Karenko et al 2), #06 (Karenko et al, 2001, 2003; Karenko et al 2),
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Table I. Outcome of TCR and chromosomal analysis
Diagnosis Patient Source Date TCR clone Chromosomal clone
Clinical outcome
(therapy given)a
MF IA #01 sk 04/99 np nd
bl 01/95 cb nc
bl 06/99 cb c CR (PUVA)
#02 sk 01/97 c nd
bl 04/96 occ c CR (PUVA)
#03 sk 10/01 c nd
bl 03/98 c c CR, relapses (PUVA, EB)
MF IB #04 sk 06/00 c c
bl 04/93 cd nc
bl 08/00 cd c PD (PUVA)
#05 sk 09/95 c nd
bl 08/96 c nc CR (EB)
#06 sk 07/97 c c
sk 03/98 c nd
bl 08/97 nc nce
bl 03/98 nc nc PD (EB)
MF IIA #07 bl 08/00 nc nc PD (multiple therapies)
MF IIB #08 sk 08/93 c c
sk 08/93 c c
bl 05/93 c c PD/DOD
#09 sk 07/98 c c
bl 09/98 occ c PD/DOD
#10 sk 08/01 c nd
bl 04/99 cd nd
bl 03/01 cd cf PD/DOD
MF IVA #11 sk 03/98 c c
bl 03/98 c c
bl 12/99 c c PD/DOD
#12 bl 10/00 cb c
bl 03/01 cb c PD/DOD
SS #13 bl 02/00 c c CR (chemo)
#14 bl 11/93 c c
bl 03/96 cg nc CR (chemo)
#15 sk 01/98 c c
ln 01/98 c c
bl 03/98 c c PD/DOD
#16 sk 02/97 c c
bl 02/97 c c PD/DOD
s.c. CTCL #17 sk 03/99 c c
bl 03/99 occ c
bl 06/99 occ cf CR (chemo)
Healthy controls #18 bl — nc nc
#19 bl — nc nc
#20 bl — nc nc
#21 bl — nc nc
#22 bl — nc nc
Psoriasis vulgaris #23 bl — nc nc
#24 bl — nc nc
#25 bl — nc nc
#26 bl — nc nc
bl, blood; sk, skin; c, clonal (if not otherwise indicated, clones were identical in all samples from a given patient); nc, non-clonal; oc, oligoclonal; nd, not
determined; np, no PCR amplification.
aCR, complete response; EB, electron beam therapy; PD, progression; DOD, died of CTCL after multiple forms of therapy; chemo, poly/
monochemotherapy.
bSkin sample not available.
cUp to four additional clones detectable.
dPredominant clone not identical with cutaneous clone.
eOne cell with the aberrations corresponding to the skin clone found.
fLater sample analyzed for chromosomal clonality.
gDifferent TCR clone in follow-up sample.
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#09–13 (Karenko et al 2), #15–17 (Karenko et al, 1999, 2001, 2003;
Karenko et al 2).
Clonal chromosomal abnormalities These were sought with
standard G-banding, comparative genomic hybridization (CGH),
and FISH techniques (multi-fluor FISH, MFISH; spectral karyotyp-
ing, SKY; centromere-specific techniques). In G-banding, a
minimum of 20 blood lymphocyte karyotypes and, if no clone
was detected, up to 100 mitoses were examined. A chromosomal
clone was defined, according to the International System for
Human Cytogenetic Nomenclature (ISCN), as the same numerical
aberration observed in at least three cells or the same structural
aberration in at least two cells (Mitelman 1995; Karenko et al,
1997). In other words, a chromosomal clone was assumed if at
least 3% of the lymphocytes studied showed the same numerical
aberration or at least 2% an identical structural aberration. For
CGH, DNA was extracted from blood lymphocytes and, after
micro-dissection of frozen skin sections, from epidermotropic
lymphocytes. All DNA copy-number changes were interpreted as
clonal (Karenko et al, 1999). SKY and MFISH were performed from
blood lymphocytes as recommended (SKY kit, Applied Spectral
Imaging, Migdal HaEmek, Israel; 24XCyte-kit, Metasystems,
Altlussheim, Germany). A clone was defined as above. Centromere-
specific FISH was carried out on interphase as well as metaphase
chromosomes (Karenko et al, 1997, 2001).
TCR rearrangement studies These studies were performed
blinded to the results of the chromosomal analyses as described
(Lukowsky et al, 2002). In brief, TCRg rearrangements were
amplified by two PCR and labelled amplicons were subjected to
fluorescence fragment analysis (FFA) on an ABI 310 PRISM CE
sequencer (PE Applied Biosystems, Weiterstadt, Germany). TCR
clonality was assessed according to peak-height ratios as clonal,
oligoclonal, or non-clonal (Fig 1a). Clonal fragment lengths were
recorded for comparison of blood and skin samples. Lymphocytes
trisomic for centromere 8 (this aberration serving as a marker) were
detected enzymatically by in situ hybridization, micro-dissected
from tissue touch preparations (Karenko et al, 2001) of patient #15
and #16, forwarded to TCRg PCR, and subsequently analyzed by
FFA and TCRg sequencing as described (Gellrich et al, 2000).
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